Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer

Key facts

Sponsor

Gynecologic Oncology Group

Principal Investigator

Don Dizon, MD

NRG Oncology

Intervention

Nintedanib(drug)

Enrollment

37 enrolled

Eligibility

18 years · FEMALE

Timeline

2011 – 2016

Study locations (30)

• Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank, California, United States
• University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
• Smilow Cancer Hospital Care Center at Saint Francis, Hartford, Connecticut, United States
• Memorial University Medical Center, Savannah, Georgia, United States
• Saint Alphonsus Cancer Care Center-Boise, Boise, Idaho, United States
• Northwestern University, Chicago, Illinois, United States
• NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
• Sudarshan K Sharma MD Limted-Gynecologic Oncology, Hinsdale, Illinois, United States
• Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
• Saint Vincent Oncology Center, Indianapolis, Indiana, United States
• University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
• Greater Baltimore Medical Center, Baltimore, Maryland, United States
• MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore, Maryland, United States
• Saint Joseph Mercy Hospital, Ann Arbor, Michigan, United States
• Michigan Cancer Research Consortium NCORP, Ann Arbor, Michigan, United States
• +15 more locations on ClinicalTrials.gov

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.